Microdissection

Groundbreaking New Procedure for Azoospermic Men Involving Minimally Invasive Sperm Mapping Combined with Extended Sperm Search and Microfreeze Leads to First Pregnancy

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ --Maze Sexual & Reproductive Health has announced the first pregnancy worldwide as a result of a new, minimally invasive procedure. Specifically, sperm are collected via Sperm Mapping, and then searched for and, if found, frozen or used fresh using Extended Sperm Search and Microfreeze (ESSM). They can then be injected into a partner's egg. The combined procedure, called Grid Needle Sperm Extraction and MicroSearch (GN-SEM), will allow some men with no sperm in the ejaculate (azoospermia) the ability to initiate a pregnancy without surgically opening up the testicle.

Key Points: 
  • Specifically, sperm are collected via Sperm Mapping, and then searched for and, if found, frozen or used fresh using Extended Sperm Search and Microfreeze (ESSM).
  • I'm extremely proud of the fact that we have profoundly changed the way we treat azoospermic and cryptospermic men.
  • With men with cryptospermia (very very few sperm in the ejaculate) we have found and frozen sperm in almost 100% of men! ''
  • As of today, Maze has 30 babies born from sperm collected through ESSM, and 97 men whose sperm are stored.

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Key Points: 
  • NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).
  • "Pillar Biosciences is committed to developing the data necessary to support the quality, accuracy and value of our leading IVD & RUO kitted products which can be used locally by laboratories to perform NGS sequencing," said Randy Pritchard, CEO of Pillar Biosciences, Inc. "We are proud to present these data in partnership with our collaborators at this year's AMP Annual Meeting as we continue to enable more laboratories globally with NGS assays that can be performed in a low-cost, high-multiplexed manner, thus enabling actionable, accessible NGS profiling results."
  • The scientific data presented at AMP will focus on Pillar Biosciences oncoReveal™ Research-Use-Only (RUO) kitted NGS products for liquid biopsy (LBx), HRD, methylation, solid tumor and automation.
  • Localized NGS-based Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Patient Care in Oncology (Room 251F: 8:00-8:50 AM MDT)
    Highly Accurate and Automated NGS assays for Efficient Localized LBx and TBx Clinical Testing in Oncology (Room 251F: 9:00-9:51 AM MDT)
    Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for The Targeted Characterization of CRC & NSCLC Samples (Poster Number: ST120)
    Robust Low Frequency Somatic Variant Detection in cfDNA Using a SLIMamp® Based Liquid Biopsy Assay (Poster Number: ST035)
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (Poster Number: ST107)
    Automation of The Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System (Poster Number: ST029)
    QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection (Poster Number: TT007)
    To UMI or Not to UMI: Obtaining Robust Low-Frequency Variant Identification for Liquid Biopsy with a SLIMamp-Based NGS Chemistry Without Molecular Barcoding (Poster Number: ST145)
    Robust Bioinformatic Method for Estimating Tumor Content in cfDNA Using Denoised Target Sequencing (Poster Number: I031)
    Pillar Biosciences oncoReveal methylQuant Panels: Accurate and Easy-to-Use Methylation NGS Assays Leveraging SLIMamp Technology (Poster Number: ST031)
    oncoReveal Fusion LBx: Single-Tube Multiplexed PCR-Based NGS assay for Detection of Multiple Gene Fusions from Cell Free RNA (Poster Number: ST041)
    Robust Detection of Copy Number Amplifications Using Pillar's oncoReveal™ Core LBx Panel with Low Input from Liquid Biopsy Samples (Poster Number: I011)
    Poster and abstract summaries of this research will be available onsite at Pillar Biosciences' booth #619.

NICO Awards $40,000 Grant to Study Genetic & Biological Make-Up of Meningioma Brain Tumors

Retrieved on: 
Thursday, May 4, 2023

INDIANAPOLIS, May 4, 2023 /PRNewswire/ -- NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, has awarded a $40,000 grant to Daniel Prevedello, MD, vice chair for Academic Affairs and director of Skull Base and Pituitary Surgery Programs at the Ohio State University (OSU) Comprehensive Cancer Center. The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions. Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.

Key Points: 
  • The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions.
  • Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.
  • Study on progression & recurrence of the most common brain tumor, meningioma, could guide new patient care decisions.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

Worldwide Laser Capture Microdissection Industry to 2027 - Featuring Epistem, Fluidigm and Gnome Diagnostics Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022

Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization.

Key Points: 
  • Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization.
  • It relies on ultraviolet (UV), infrared, and immunofluorescence laser beams to harvest pure enriched cell populations from tissue, blood, and semen samples.
  • What has been the impact of COVID-19 on the global laser capture microdissection market?
  • What is the structure of the global laser capture microdissection market and who are the key players?

Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing

Retrieved on: 
Monday, May 16, 2022

MILAN, May 16, 2022 /PRNewswire/ -- Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection. Cellular fraction is gently stabilized on proprietary, nanocoated SBS slides for rare cell detection, including CTCs, while plasma is made available for the analysis of cell-free content.

Key Points: 
  • This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection.
  • See.d processes fresh blood collected in EDTA tubes shortly after collection (within 4 to 6 hours) favoring maximum sample integrity.
  • "This is a key development milestone not just for Tethis but hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi, Chief Technology Officer of the company.
  • "It's a first step towards true multi-analytical, standardized liquid biopsy tests involving all possible tumor content released in the bloodstream.

Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing

Retrieved on: 
Monday, May 16, 2022

MILAN, May 16, 2022 /PRNewswire/ -- Tethis S.p.A announces the release of See.d®, the first universal blood sample preparator for liquid biopsy analysis. This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection. Cellular fraction is gently stabilized on proprietary, nanocoated SBS slides for rare cell detection, including CTCs, while plasma is made available for the analysis of cell-free content.

Key Points: 
  • This innovative technology performs a completely automated and standardized preparation of a blood sample at the point of blood collection.
  • See.d processes fresh blood collected in EDTA tubes shortly after collection (within 4 to 6 hours) favoring maximum sample integrity.
  • "This is a key development milestone not just for Tethis but hopefully for liquid biopsy adoption" said Mr. Gian Martino Franchi, Chief Technology Officer of the company.
  • "It's a first step towards true multi-analytical, standardized liquid biopsy tests involving all possible tumor content released in the bloodstream.

Popular Male Infertility Procedure Carries Risk of Testosterone Impairment

Retrieved on: 
Thursday, May 5, 2022

LOS ANGELES, May 5, 2022 /PRNewswire/ -- New research reveals the risk of long-term testosterone impairment for men undergoing microTESE, a popular surgery that enables men with nonobstructive azoospermia to become fathers. Led by Dr. Paul Turek, the study points to the need for precision diagnostics prior to invasive sperm retrieval surgeries.

Key Points: 
  • LOS ANGELES, May 5, 2022 /PRNewswire/ -- New research reveals the risk of long-term testosterone impairment for men undergoing microTESE, a popular surgery that enables men with nonobstructive azoospermia to become fathers.
  • He added, "It's the other job of the testicle to make testosterone, and this process is at risk when sperm retrieval surgeries are undertaken 'blindly,' that is without diagnostic guidance."
  • The study compared testosterone levels in men before and after blind microTESE (microdissection testicular sperm extraction) surgical procedures.
  • The goal was to define what proportion of men did not recover testosterone levels after having surgery and how many might require lifelong testosterone replacement.

$2.15 Billion Spatial Genomics and Transcriptomics Markets - Global Opportunity Analysis and Industry Forecast, 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 29, 2022

The "Spatial Genomics and Transcriptomics Market by Technique, Product Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spatial Genomics and Transcriptomics Market by Technique, Product Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • In addition, spatial genomics and transcriptomics provide information on immune cells and characterize the subcellular distribution of transcripts in a variety of situations.
  • The major factors that impact the growth of the spatial genomics and transcriptomic market include increase in adoption of spatial genomics and transcriptomics technologies, owing to their various applications.
  • The global spatial genomics and transcriptomics market also declined in 2020 due to global economic recession led by COVID-19.

Bionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis

Retrieved on: 
Friday, February 11, 2022

However, KT requires cultured cells, which are difficult to obtain with POC samples, and as a result, KT test failures are frequent.

Key Points: 
  • However, KT requires cultured cells, which are difficult to obtain with POC samples, and as a result, KT test failures are frequent.
  • In addition to failing to culture, POC samples are highly heterogeneous and frequently contaminated with maternal cells, making any cytogenetic or molecular analysis challenging.
  • Previous studies have demonstrated that OGM is highly concordant with KT, and because of its higher resolution, OGM often identifies additional genetic aberrations missed by other methods.
  • The Companys mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Global Laser Capture Microdissection Market to Reach $195.2 Million by 2026

Retrieved on: 
Tuesday, October 19, 2021

SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Capture Microdissection - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Capture Microdissection - Global Market Trajectory & Analytics" .
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Laser Capture Microdissection estimated at US$108.6 Million in the year 2020, is projected to reach a revised size of US$195.2 Million by 2026, growing at a CAGR of 10.1% over the analysis period.
  • The U.S. Market is Estimated at $36.3 Million in 2021, While China is Forecast to Reach $33.9 Million by 2026
    The Laser Capture Microdissection market in the U.S. is estimated at US$36.3 Million in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com )is a renowned market research publisher the world`s only influencer driven market research company.